Why doesn't reducing exacerbations decrease COPD mortality?

The Lancet Respiratory Medicine

Volumn 2, Issue 9, 2014, Pages 681-683

  Brusselle, Guy ^a,b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; AIRWAY OBSTRUCTION; BODY MASS; CANCER SCREENING; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; DISEASE EXACERBATION; DYSPNEA; ETHNICITY; EXERCISE; FORCED EXPIRATORY VOLUME; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; INTERNAL VALIDITY; LUNG CANCER; LUNG FUNCTION; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; NOTE; PHENOTYPE; POPULATION RESEARCH; PRACTICE GUIDELINE; PREDICTION; PREVALENCE; PRIMARY MEDICAL CARE; PROGNOSIS; QUALITY OF LIFE; SECONDARY HEALTH CARE; SEX DIFFERENCE; SEX RATIO; SMOKING; SMOKING CESSATION; SURVIVAL RATE; SYMPTOMATOLOGY; TERTIARY HEALTH CARE; TREATMENT INDICATION; DISEASE COURSE; PATHOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

DISEASE PROGRESSION; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84908025023     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(14)70163-8     Document Type: Note

References (14)

1. Rodriguez-Roisin R Toward a consensus definition for copd exacerbations*. Chest 2000, 117(suppl 2):s398-s401.
2. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008, 31:416-469.
3. Wedzicha JA, Seemungal TAR COPD exacerbations: defining their cause and prevention. Lancet 2007, 370:786-796.
4. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010, 182:598-604.
5. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011, 184:662-671.
6. Kruis AL, Ställberg B, Jones RCM, et al. Primary Care COPD patients compared with large pharmaceutically-sponsored COPD studies: an UNLOCK validation study. PLoS One 2014, 9:e90145.
7. Hurst JR, Vestbo JR, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. New Engl J Med 2010, 363:1128-1138.
8. Lange P, Marott JL, Vestbo J, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification. Am J Respir Crit Care Med 2012, 186:975-981.
9. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002, 57:847-852.
10. Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. New Engl J Med 2011, 365:1184-1192.
11. Garcia-Aymerich J, Serra Pons I, Mannino DM, Maas AK, Miller DP, Davis KJ Lung function impairment, COPD hospitalisations and subsequent mortality. Thorax 2011, 66:585-590.
12. Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 186:155-161.
13. Briggs A, Spencer M, Wang H, Mannino D, Sin DD Development and validation of a prognostic index for health outcomes in chronic obstructive pulmonary disease. Arch Intern Med 2008, 168:71-79.
14. Celli B, Vestbo J, Jenkins CR, et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. Am J Respir Crit Care Med 2011, 183:317-322.